Please provide your email address to receive an email when new articles are posted on . Hand-foot syndrome is a painful adverse event from chemotherapy, particularly capecitabine. Data show an ...

CHICAGO--(BUSINESS WIRE)--Emalex Biosciences today announced that the first patient was dosed in its Expanded Access Program for ecopipam, an investigational first-in-class D1 receptor antagonist in ...

(NEXSTAR) – More and more states have legalized marijuana in some form in recent years. The federal government also appears poised to reschedule marijuana following a December executive order from ...

AS THE MONTH OF FEBRUARY COMES TO A CLOSE, IT BRINGS AWARENESS THAT’S AHEAD. ON SATURDAY, FEBRUARY 28TH. IN THIS STORY, YOU HEAR HOW A RARE DISEASE BROUGHT PAIN AND SUFFERING TO A WOMAN. BUT NOW SHE ...

Acadia Pharmaceuticals said that drug regulators in Europe are leaning toward rejecting its application for a neurodevelopmental disorder treatment. The company said Monday it was informed by a ...

– Designation recognizes the potential of ETX101 to address a serious condition with high unmet need – Encoded Therapeutics, Inc. (“Encoded”), a clinical-stage biotechnology company developing ...

Fatigue can stem from a variety of illnesses and life stressors, but when that exhaustion lasts for months — often following an infection — it may indicate a condition called chronic fatigue syndrome.

Credit: Acadia. Daybue Stix, a strawberry-flavored trofinetide powder mixable with water-based liquids, gains FDA approval for Rett syndrome treatment. Acadia expects to have the new formulation ...

Biologics, including GLP-1 analogs and PCSK9 inhibitors, are advancing treatment options for metabolic syndrome components like type 2 diabetes and dyslipidemia. GLP-1 receptor agonists improve ...

According to reporting from Reuters, reviewers at the agency pointed to an inability to differentiate from placebo to justify rejecting the drug, but an FDA office director approved the drug anyway.